Core Viewpoint - Idorsia Ltd announces the resignation of Dr. Srishti Gupta as CEO and Board member, with the Board initiating a search for her successor while Jean-Paul Clozel will serve as interim CEO [1][2][4]. Group 1: Leadership Changes - Dr. Srishti Gupta has mutually agreed to step down from her role as CEO and from the Board of Directors [1]. - The Board has begun the process of finding a new CEO with extensive pharmaceutical leadership experience [4]. - Jean-Paul Clozel, the Chairman of the Board, will take over day-to-day operations as interim CEO until a successor is appointed [2][4]. Group 2: Acknowledgments and Future Outlook - Jean-Paul Clozel expressed gratitude for Dr. Gupta's significant contributions during her tenure, highlighting her commitment to the company's mission [3]. - Dr. Gupta reflected on her honor in leading Idorsia and the achievements made in advancing patient care [3]. - The Board plans to propose new independent candidates for election at the upcoming Annual General Meeting (AGM) to bring fresh perspectives [4]. Group 3: Company Overview - Idorsia aims to discover, develop, and commercialize innovative medicines, positioning itself as a leading biopharmaceutical company with a strong scientific foundation [6]. - The company is headquartered near Basel, Switzerland, and has a dedicated team focused on drug discovery and development, including a promising pipeline and partnerships [7].
Idorsia announces management change
Globenewswire·2026-03-16 06:00